Cargando…

P1044: REAL-WORLD RUXOLITINIB TREATMENT PATTERN IN MYELOFIBROSIS PATIENTS WITH THROMBOCYTOPENIA

Detalles Bibliográficos
Autores principales:	Mei, J., Wang, Y., Kabir, S., Ichikawa, N., Iino, S., Lebedinsky, C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430455/ http://dx.doi.org/10.1097/01.HS9.0000847044.61674.8e

Ejemplares similares

P1057: REAL-WORLD UTILIZATION OF FEDRATINIB FOR MYELOFIBROSIS FOLLOWING RUXOLITINIB FAILURE
por: Harrison, C., et al.
Publicado: (2022)

P1058: REAL-WORLD OUTCOMES WITH FEDRATINIB THERAPY IN PATIENTS WITH PRIMARY MYELOFIBROSIS POST-RUXOLITINIB DISCONTINUATION
por: Passamonti, F., et al.
Publicado: (2022)

P1047: REAL-WORLD SAFETY OF RUXOLITINIB IN PATIENTS WITH INTERMEDIATE OR HIGH RISK OF PRIMARY MYELOFIBROSIS, POST-POLYCYTHEMIA VERA MYELOFIBROSIS OR POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS IN CHINA
por: Xu, Z., et al.
Publicado: (2022)

P1069: RETROSPECTIVE COMPARISON OF PATIENT OUTCOMES ON PACRITINIB VERSUS RUXOLITINIB IN PATIENTS WITH MYELOFIBROSIS AND THROMBOCYTOPENIA
por: Harrison, C., et al.
Publicado: (2022)

P1052: A REAL-WORLD STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SELINEXOR IN COMBINATION WITH RUXOLITINIB IN PATIENTS WITH MYELOFIBROSIS
por: Duan, Minghui, et al.
Publicado: (2023)

P1010: RUXOLITINIB IN MYELODEPLETIVE MYELOFIBROSIS: RESPONSE, TOXICITY, AND OUTCOME
por: Palandri, F., et al.
Publicado: (2022)

P991: IMPAIRMENT OF TCR SIGNALLING IN PATIENTS WITH MYELOFIBROSIS TREATED WITH RUXOLITINIB
por: Harrington, P., et al.
Publicado: (2022)

P1059: REAL-WORLD TREATMENT PATTERNS AND HEALTHCARE RESOURCE UTILIZATION IN MYELOFIBROSIS PATIENTS WITH ANEMIA
por: Mascarenhas, John, et al.
Publicado: (2023)

Ruxolitinib for myelofibrosis
por: GU, LIAN, et al.
Publicado: (2013)

P1061: INDIRECT TREATMENT COMPARISONS OF FEDRATINIB VERSUS NAVITOCLAX PLUS RUXOLITINIB: EFFECT ON SPLEEN VOLUME AND SYMPTOMS IN RUXOLITINIB-EXPOSED MYELOFIBROSIS PATIENTS
por: Abraham, P., et al.
Publicado: (2022)

Ruxolitinib Re-Treatment in Patients with Myelofibrosis: Real-World Evidence on Patient Characteristics and Outcomes
por: Gerds, Aaron T., et al.
Publicado: (2022)

P1018: TREND OF CIRCULATING CD34+ CELLS IN MYELOFIBROSIS PATIENTS TREATED WITH RUXOLITINIB
por: Cattaneo, D., et al.
Publicado: (2022)

P1044: REDUCTION IN RED BLOOD CELL TRANSFUSION BURDEN: A NOVEL LONGITUDINAL TIME-DEPENDENT ANALYSIS IN PATIENTS WITH TRANSFUSION-DEPENDENT MYELOFIBROSIS TREATED WITH MOMELOTINIB
por: Harrison, Claire, et al.
Publicado: (2023)

Impact of ruxolitinib on survival of patients with myelofibrosis in the real world: update of the ERNEST Study
por: Guglielmelli, Paola, et al.
Publicado: (2022)

Real-World Assessment of Clinical Outcomes in Patients with Lower-Risk Myelofibrosis Receiving Treatment with Ruxolitinib
por: Davis, Keith L., et al.
Publicado: (2015)

Management of Myelofibrosis during Treatment with Ruxolitinib: A Real-World Perspective in Case of Resistance and/or Intolerance
por: Breccia, Massimo, et al.
Publicado: (2022)

Real-life ruxolitinib experience in intermediate-risk myelofibrosis
por: Arikan, Fatma, et al.
Publicado: (2021)

Ruxolitinib in Myelofibrosis and Polycythemia Vera
por: Wolfe, Leah
Publicado: (2016)

Ruxolitinib in myelofibrosis: to be or not to be an immune disruptor
por: Manduzio, Palma
Publicado: (2017)

P1029: MATCHING-ADJUSTED INDIRECT COMPARISON (MAIC) OF PELABRESIB (CPI-0610) IN COMBINATION WITH RUXOLITINIB VS RUXOLITINIB OR FEDRATINIB MONOTHERAPY IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS
por: Gupta, V., et al.
Publicado: (2022)

Ruxolitinib for the treatment of myelofibrosis: its clinical potential
por: Ostojic, Alen, et al.
Publicado: (2012)

Definition and management of ruxolitinib treatment failure in myelofibrosis
por: Pardanani, A, et al.
Publicado: (2014)

Real-world survival of US patients with intermediate- to high-risk myelofibrosis: impact of ruxolitinib approval
por: Verstovsek, Srdan, et al.
Publicado: (2021)

P1005: A PHASE 1, OPEN-LABEL, DOSE-ESCALATION STUDY OF SELINEXOR PLUS RUXOLITINIB IN PATIENTS WITH TREATMENT-NAÏVE MYELOFIBROSIS
por: Ali, H., et al.
Publicado: (2022)

P1003: RUXOLITINIB AND MAGROLIMAB INCREASES CALRETICULIN IN MYELOFIBROSIS CD34+ CELLS IN VITRO. PROOF OF CONCEPT FOR COMBINATION THERAPY.
por: Rinaldi, Ciro, et al.
Publicado: (2023)

P991: ADDING NAVTEMADLIN (NVTM) TO RUXOLITINIB (RUX) POTENTIATES APOPTOSIS IN MYELOBLASTS FROM PATIENTS (PTS) WITH MYELOFIBROSIS (MF)
por: Clevenger, Tracy, et al.
Publicado: (2023)

P1021: JAKTINIB IN PATIENTS WITH MYELOFIBROSIS WHO WERE INTOLERANT TO RUXOLITINIB: AN OPEN-LABEL, SINGLE-ARM PHASE 2B STUDY
por: Zhang, Yi, et al.
Publicado: (2023)

P1060: REAL-WORLD CLINICAL OUTCOMES AFTER 3 AND 6 MONTHS OF TREATMENT WITH FEDRATINIB FOLLOWING RUXOLITINIB FAILURE
por: Mascarenhas, J., et al.
Publicado: (2022)

Efficacy of ruxolitinib on hepatomegaly in patients with myelofibrosis
por: Verstovsek, S, et al.
Publicado: (2016)

Ruxolitinib therapy and telomere length in myelofibrosis
por: Caocci, G, et al.
Publicado: (2016)

Management of myelofibrosis after ruxolitinib failure
por: Harrison, Claire N, et al.
Publicado: (2020)

P1055: CLINICAL AND GENETIC RESULTS OF THE PHASE IB/II TRIAL MPNSG-0212: RUXOLITINIB PLUS POMALIDOMIDE IN MYELOFIBROSIS WITH ANEMIA
por: Stegelmann, F., et al.
Publicado: (2022)

P1018: UPDATED RESULTS FROM MANIFEST ARM 2: EFFICACY AND SAFETY OF PELABRESIB (CPI-0610) AS ADD-ON TO RUXOLITINIB IN MYELOFIBROSIS
por: Kremyanskaya, Marina, et al.
Publicado: (2023)

Reactivation of Pulmonary Tuberculosis following Treatment of Myelofibrosis with Ruxolitinib
por: Abidi, Maheen Z., et al.
Publicado: (2016)

P1030: MANIFEST-2, A GLOBAL, PHASE 3, RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROL STUDY OF PELABRESIB (CPI-0610) AND RUXOLITINIB VS PLACEBO AND RUXOLITINIB IN JAK INHIBITOR-NAÏVE MYELOFIBROSIS PATIENTS
por: Harrison, C., et al.
Publicado: (2022)

P1047: AIPSS-MF MACHINE LEARNING MODEL AS USEFUL PROGNOSTIC SCORE COMPARED TO IPSS IN THE SETTING OF MYELOFIBROSIS PATIENTS TREATED WITH RUXOLITINIB
por: Duminuco, Andrea, et al.
Publicado: (2023)

P1020: SELINEXOR (SEL) PLUS RUXOLITINIB (RUX) IN JAK INHIBITOR (JAKI) TREATMENT-NAÏVE PATIENTS WITH MYELOFIBROSIS: UPDATED RESULTS FROM XPORT-MF-034
por: Ali, Haris, et al.
Publicado: (2023)

P1027: UPDATED DURABILITY OF RESPONSE AND SAFETY IN MANIFEST ARM 3: PELABRESIB (CPI-0610) COMBINED WITH RUXOLITINIB FOR JAK INHIBITOR TREATMENT-NAÏVE PATIENTS WITH MYELOFIBROSIS
por: Harrison, Claire, et al.
Publicado: (2023)

P1028: MYELOFIBROSIS (MF) TREATED WITH RUXOLITINIB (RUX) MONOTHERAPY: PREDICTORS OF EARLY DISCONTINUATION AND DEATH ON TREATMENT. THE SHORT-TERM RUX PROGNOSTIC MODEL (STR-PM)
por: Palandri, Francesca, et al.
Publicado: (2023)

Carfilzomib Enhances the Suppressive Effect of Ruxolitinib in Myelofibrosis
por: Claudiani, Simone, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ils3molicbm6e6r94oualqtqv1